| 7 May 2012 |
| 07:00 20:00 | | Registration
|
| 08:30 09:15 | | Plenary Lecture 3
Location: Main Hall
Chair: Chair(s): M. Reincke (Germany)
|
| 08:30 | PL3 PL3 | Mating, sex and the immune system in humans and fish
M. Milinski (Germany) |
| | | |
| 09:30 11:00 | | Oral Communication Session 1 - Pituitary Clinical I
Location: Hall A
Chairs: Chair(s): M. Marazuela (Spain) & P. Burman (Sweden)
|
| 09:30 | OC1.1 OC1.1 | Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study
A-M. Colao (Italy) |
| | | |
| 09:45 | OC1.2 OC1.2 | Patients with Cushing’s disease achieve normal urinary cortisol with LCI699, a potent 11β-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study
X. Bertagna (France) |
| | | |
| 10:00 | OC1.3 OC1.3 | Efficacy and safety of long-term treatment with pegvisomant in acromegaly: Italian pegvisomant observational study (acrostudy)
A. Bianchi (Italy) |
| | | |
| 10:15 | OC1.4 OC1.4 | A multi-centre audit of the prevalence of cardiac valvulopathy in patients treated with dopamine agonists for hyperprolactinaemia
W. Drake (UK) |
| | | |
| 10:30 | OC1.5 OC1.5 | Initial hypothalamic involvement is the major risk factor for impaired prognosis and quality of life in childhood craniopharyngioma regardless of chosen treatment strategies – Results of KRANIOPHARYNGEOM 2000
H. Müller (Germany) |
| | | |
| 10:45 | OC1.6 OC1.6 | Normal weight adult patients with Prader-Willi syndrome are not protected from insulin resistance during treatment with growth hormone: Results from a 12 month prospective study
A. Jørgensen (Norway) |
| | | |
| 09:30 11:00 | | Oral Communication Session 2 - Thyroid Clinical I
Location: Hall B
Chairs: Chair(s): L. Bartalena (Italy) & I. Al-Ibrashy (Egypt)
|
| 09:30 | OC2.1 OC2.1 | Overt hyperthyroidism is associated with increased mortality. A nationwide register-based study of disease discordant Danish twins
F. Brandt (Denmark) |
| | | |
| 09:45 | OC2.2 OC2.2 | Identification and functional analysis of DUOX2 variants: Bialleclic mutations are associated with permanent congenital hypothyroidism
M. Muzza (Italy) |
| | | |
| 10:00 | OC2.3 OC2.3 | Thyroid hormone levels in euthyroid young men are associated with body composition and metabolic parameters
G. Roef (Belgium) |
| | | |
| 10:15 | OC2.4 OC2.4 | The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
C. Moran (UK) |
| | | |
| 10:30 | OC2.5 OC2.5 | Thyroid spongiform nodules are the best candidates for percutaneous laser ablation. A 5 year follow-up study in 72 patients
G. S. Bortolani (Italy) |
| | | |
| 10:45 | OC2.6 OC2.6 | Concurrent presence of nonendocrine autoimmune diseases with Hashimoto's thyroiditis: A systematic assessment on more than 5000 consecutive patients
M. Cetanni (Italy) |
| | | |
| 09:30 11:00 | | Oral Communication Session 3 - Diabetes Clinical
Location: Hall C
Chairs: Chair(s): V. Pirags (Latvia) & K. Abdalla (Egypt)
|
| 09:30 | OC3.1 OC3.1 | Common variants of monogenic diabetes genes may affect beta cell functional mass in patients with newly diagnosed type 2 diabetes
S. Bonetti (Italy) |
| | | |
| 09:45 | OC3.2 OC3.2 | Weight-loss independent metabolic benefits of gastric bypass surgery? Experiences from the Swedish Obese Subjects (SOS) study
M. Peltonen (Finland) |
| | | |
| 10:00 | OC3.3 OC3.3 | Diabetic ketoacidosis at diagnosis influences complete remission after treatment of hematopoietic stem cell transplantation in adolescents with type 1 diabetes
W. Gu (China) |
| | | |
| 10:15 | OC3.4 OC3.4 | Glucose lowering therapies and cancer specific mortality in adult insulin-treated diabetes
S. Loacara (Romania) |
| | | |
| 10:30 | OC3.5 OC3.5 | Study of toll like receptor 2 and 4 expression in monocytes in type 1 diabetes mellitus with and without micro-vascular complications
R. Abd El Baki (Egypt) |
| | | |
| 10:45 | OC3.6 OC3.6 | Glucose disorders exert a detrimental effect on total brain volume in the elderly: a 2-year prospective MRI study
K. Samaras (Australia) |
| | | |
| 09:30 11:00 | | Oral Communication Session 4 - Pituitary Basic
Location: Hall D
Chairs: Chair(s): L. Hofland (The Netherlands) & M. Theodoropoulou (Germany)
|
| | Blank Abstract
|
| | | |
| 09:30 | OC4.1 OC4.1 | Obestatin plays an opposite role in the regulation of pituitary somatotrope and corticotrope function in primates and mice
R. Luque (Spain) |
| | | |
| 09:45 | OC4.2 OC4.2 | Transcriptional regulation of prolactin by oestrogen in vivo.
A. Patist (UK) |
| | | |
| 10:00 | OC4.3 OC4.3 | miR-26a targets PRKCD in ACTH pituitary adenoma
E. Gentilin (Italy) |
| | | |
| 10:15 | OC4.4 OC4.4 | Identification of coupling specificity between somatostatin receptor 5 (SST5) and G proteins by a bioluminescence resonance energy transfer (BRET) technique: the role of GoA protein
E. Peverelli (Italy) |
| | | |
| 10:30 | OC4.5 OC4.5 | Targeting the IGF-IR system in pituitary tumors in vitro: antiproliferative action & pitfalls
M. Theodoropoulou (Germany) |
| | | |
| 10:45 | OC4.6 OC4.6 | Cell cycle G2/M transition is modulated by microRNAs in pituitary adenomas
H. Butz (Hungary) |
| | | |
| 09:30 11:00 | | Oral Communication 5 - Obesity Basic
Location: Hall E
Chairs: Chair(s): J. Gimble (USA) & S. Farooqi (UK)
|
| 09:30 | OC5.1 OC5.1 | Growth hormone ameliorates impaired glucose tolerance in obese mice by modifying the visceral fat condition through adiponectin
Y. Okamoto (Japan) |
| | | |
| 09:45 | OC5.2 OC5.2 | Production of galectin-1, -3, -9 and -12 in adipose tissue of lean and obese mice
G. Fantuzzi (United States) |
| | | |
| 10:00 | OC5.3 OC5.3 | Insulin action in brown adipose tissue is compromised during diet-induced obesity
C. Quarta (Italy) |
| | | |
| 10:15 | OC5.4 OC5.4 | Bile acid binding resin shows anti-obese effect through the modifications of intestinal microbiota
Y. Kusumoto (Japan) |
| | | |
| 10:30 | OC5.5 OC5.5 | Development of leptin deficient rat - evidence for its superiority over mouse as a model for human obesity
M. Aizawa-Abe (Japan) |
| | | |
| 10:45 | OC5.6 OC5.6 | Semaphorin 3C-a novel adipokine modulating human adipose tissue plasticity in weight change
M. Rydén (Sweden) |
| | | |
| 09:30 11:00 | | Oral Communication Session 6 - Female Reproduction Basic
Location: Hall F
Chairs: Chair(s): C. Elias (USA) & M. Simoni (Italy)
|
| 09:30 | OC6.1 OC6.1 | GnRH release failure in hyperprolactinemia is caused by a kisspeptin deficiency
N. Binart (France) |
| | | |
| 09:45 | OC6.2 OC6.2 | Ghrelin modulates fertilization, early embryo development and implantation
A. Martini (Argentina) |
| | | |
| 10:00 | OC6.3 OC6.3 | LH and hCG produce different responses in human granulosa lutein cells in vitro.
L. Casarini (Italy) |
| | | |
| 10:15 | OC6.4 OC6.4 | Female fertility and activin-stimulated Fshb expression do not require SMAD2/3 in murine gonadotropes
J. Fortin (Canada) |
| | | |
| 10:30 | OC6.5 OC6.5 | Dihydrotestosterone treatment in mice induces a persistent polycystic ovary syndrome phenotype
E. van Houten (The Netherlands) |
| | | |
| 10:45 | OC6.6 OC6.6 | Kit ligand-c-kit interaction regulates estradiol production by rat granulosa cells via oocyte factors
T. Miyoshi (Japan) |
| | | |
| 09:30 11:00 | | Oral Communication Session 7 - Adrenal Clinical
Location: Hall G
Chairs: Chair(s): B. Allolio (Germany) & J. Newell-Price (UK)
|
| 09:30 | OC7.1 OC7.1 | Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year
S. Hescot (France) |
| | | |
| 09:45 | OC7.2 OC7.2 | Activation of the PKA pathway triggers formation of an illicit serotonergic regulatory loop in primary pigmented nodular adrenal disease (PPNAD) tissues associated with Cushing’s syndrome
Z. Bram (France) |
| | | |
| 10:00 | OC7.3 OC7.3 | Ribonucleotide reductase large subunit (RRM1) gene expression predicts efficacy of adjuvant mitotane in adrenocortical cancer
M. Volante (Italy) |
| | | |
| 10:15 | OC7.4 OC7.4 | Differential diagnosis of primary aldosteronism by peripheral plasma levels of 18-oxo-cortisol - a noninvasive method with a high specificity
F. Satoh (Japan) |
| | | |
| 10:30 | OC7.5 OC7.5 | Continuous subcutaneous hydrocortisone infusion as replacement therapy in Addison’s disease
M. Øksnes (Norway) |
| | | |
| 10:45 | OC7.6 OC7.6 | Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study
G. Di Dalmazi (Italy) |
| | | |
| 09:30 11:00 | | Oral Communication Session 8 - Bone
Location: Hall H
Chair: Chair(s): C. Marcocci (Italy)
|
| 09:30 | OC8.1 OC8.1 | Hypophosphatasia: Enzyme replacement therapy (ENB-0040) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults
N. Kreher (USA) |
| | | |
| 09:45 | OC8.2 OC8.2 | Comparison of high protein and normal protein weight loss diets on bone density in overweight post-menopausal women
D. Jesudason (Australia) |
| | | |
| 10:00 | OC8.3 OC8.3 | Profiling insulin like factor 3 (INSL3) signaling in human osteoblasts
A. Ferlin (Italy) |
| | | |
| 10:15 | OC8.4 OC8.4 | Radiological vertebral fractures in hospitalized elderly patients with heart failure
G. Mazziotti (Italy) |
| | | |
| 10:30 | OC8.5 OC8.5 | Pathogenetic chromosomal rearrangements in a large series of patients with pseudohypoparathyroidism type I
F. Marta Elli (Italy) |
| | | |
| 10:45 | OC8.6 OC8.6 | Simultaneous gain and loss of methylation at imprinted loci in a subset of patients with pseudohypoparathyroidism type 1b and GNAS epimutations
A. Linglart (France) |
| | | |
| 09:30 11:00 | | Oral Communication 9 - Endocrine Tumours & Translation
Location: Basilica
Chairs: Chair(s): K. Oberg (Sweden) & A. Grossman (UK)
|
| 09:30 | OC9.1 OC9.1 | Temozolomide therapy for progressive metastatic paraganglioma/pheochromocytoma: SDHB mutation as a prognosis biomarker for efficacy
J. Hadoux (France) |
| | | |
| 09:45 | OC9.2 OC9.2 | Growth hormone protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells
M. Minoia (Italy) |
| | | |
| 10:00 | OC9.3 OC9.3 | The central role of estrogen receptor α in IGF-II dependent adrenocortical carcinoma (ACC) cell proliferation suggests the use of selective estrogen receptor modulators (SERMs) for the treatment of ACC
V. Pezzi (Italy) |
| | | |
| 10:15 | OC9.4 OC9.4 | Functional characterization of mutations in the multiple endocrine neoplasia type 1 (MEN1) gene suggest therapeutic strategies
G. Hendy (Canada) |
| | | |
| 10:30 | OC9.5 OC9.5 | Glucagon-like peptide 1 receptor (GLP-1R) imaging for the preoperative localization of benign insulinomas in 30 patients
E. Christ (Switzerland) |
| | | |
| 10:45 | OC9.6 OC9.6 | First in vitro study of human gastroenteropancreatic-neuroendocrine tumors: Comparative effect of octreotide and pasireotide
A. Mohamed (France) |
| | | |
| 09:30 11:00 | | Endocrine Nurses' Session: Puberty Induction and Sex Steroid Replacement in Young Adults
Generously Supported By Novartis
Location: Polveriera
Chairs: Chair(s): J. Foote (USA) & P. Bouchard (France)
|
| 09:30 | EN1.1 EN1.1 | Puberty induction in males and females
C. Brain (UK) |
| | | |
| 10:00 | EN1.2 EN1.2 | The role of the endocrine nurse in puberty induction
M. Keil (USA) |
| | | |
| 10:15 | EN1.3 EN1.3 | Sex steroid replacement in young males and females
G. Conway (UK) |
| | | |
| 10:45 | EN1.4 EN1.4 | Choosing the right sex steroid replacement option for patients: the role of the endocrine nurse
S. Shalet (UK) |
| | | |
| 09:30 11:30 | | ISE General Council Meeting (Invitation Only)
Location: Teatrino
|
| 11:00 11:30 | | Coffee, Posters & Exhibition
Exhibition Hall & Poster Hall
|
| 11:30 12:30 | | Debate 2: This house believes that calcium supplementation causes heart attacks
For: I. Reid (New Zealand); Against: C. Weaver (USA)
Location: Main Hall
Chair: Chair(s): J. Bollerslev (Norway)
|
| 11:30 13:15 | | ISE Travel Grant Reception (Invitation Only)
|
| 11:30 12:15 | | Meet the Expert 1 - Repeated
Location: Hall A
|
| 11:30 | MTE1 MTE1 | Adrenal incidentaloma and subclinical Cushing's syndrome
P. Stewart (UK) |
| | | |
| 11:30 12:15 | | Meet the Expert 2 - Repeated
Location: Hall B
|
| 11:30 | MTE2 MTE2 | Approach to the patient with Cushing's disease after pituitary surgery failure
M. Toth (Hungary) |
| | | |
| 11:30 12:15 | | Meet the Expert 3 - Repeated
Location: Hall C
|
| 11:30 | MTE3 MTE3 | Osteoporosis in men
U. Gruntmanis (USA) |
| | | |
| 11:30 12:15 | | Meet the Expert 4 - Repeated
Location: Hall D
|
| 11:30 | MTE4 MTE4 | Challenges of transsphenoidal pituitary surgery
P. Cappabianca (Italy) |
| | | |
| 11:30 12:15 | | Meet the Expert 5 - Repeated
Location: Hall E
|
| MTE5 MTE5 | Discussions of common but difficult thyroid cancer cases
L. Wartofsky (USA) |
| | | |
| 11:30 12:15 | | Meet the Expert 6 - Repeated
Location: Hall F
|
| 11:30 | MTE6 MTE6 | Clinical management of adrenocortical carcinoma
M. Terzolo (Italy) |
| | | |
| 11:30 12:15 | | Meet the Expert 7 - Repeated
Location: Hall G
|
| 11:30 | MTE7 MTE7 | Pregnancy and pituitary disorders
Z. Karaca (Turkey) |
| | | |
| 11:30 12:15 | | Meet the Expert 8 - Repeated
Location: Hall H
|
| 11:30 | MTE8 MTE8 | Diagnosis and treatment of precocious puberty
L. Ghizzoni (Italy) |
| | | |
| 12:25 13:10 | | Meet the Expert 9 - Repeated
Location: Hall A
|
| 12:25 | MTE9 MTE9 | Diagnosis and treatment of SIADH
C. Thompson (Ireland) |
| | | |
| 12:25 13:10 | | Meet the Expert 10 - Repeated
Location: Hall B
|
| 12:25 | MTE10 MTE10 | Elastosonography in the evaluation of thyroid and parathyroid lesions
M. Erdogan (Turkey) |
| | | |
| 12:25 13:10 | | Meet the Expert 11 - Repeated
Location: Hall C
|
| 12:25 | MTE11 MTE11 | Diagnosis and treatment considerations in autoimmune polyendocrine syndrome type 1
O. Kampe (Sweden) |
| | | |
| 12:25 13:10 | | Meet the Expert 12 - Repeated
Location: Hall D
|
| 12:25 | MTE12 MTE12 | Goitre throughout the paediatric ages
M. Polak (France) |
| | | |
| 12:25 13:10 | | Meet the Expert 13 - Repeated
Location: Hall E
|
| 12:25 | MTE13 MTE13 | Graves' ophthalmopathy
W. Wiersinga (The Netherlands) |
| | | |
| 12:25 13:10 | | Meet the Expert 14 - Repeated
Location: Hall F
|
| 12:25 | MTE14 MTE14 | Hirsutism
K. Unluhizarci (Turkey) |
| | | |
| 12:25 13:10 | | Meet the Expert 15 - Repeated
Location: Hall G
|
| 12:25 | MTE15 MTE15 | Pituitary tumours in adolescents and adults
M. Andersen (Denmark) |
| | | |
| 12:25 13:10 | | Meet the Expert 16 - Repeated
Location: Hall H
|
| 12:25 | MTE16 MTE16 | Management of non-functioning pituitary adenomas
N. Karavitaki (UK) |
| | | |
| 12:30 13:15 | | Lunch, Posters & Exhibition
ESE President meets ESE New Members (invitation only)
Exhibition Hall & Poster Hall
|
| 13:15 14:45 | | Symposium 26: TSH Receptor
Location: Hall A
Chairs: Chair(s): R. Paschke (Germany) & E. Martino (Italy)
|
| 13:15 | S26.1 S26.1 | Low-molecular weight antagonists of the TSH receptor
M. Gershengorn (USA) |
| | | |
| 13:45 | S26.2 S26.2 | Epitope geography and intracellular pathways of TSH receptor antibodies
T. Davis (USA) |
| | | |
| 14:15 | S26.3 S26.3 | Structure and function of TSH receptor
H. Biebermann (Germany) |
| | | |
| 13:15 14:45 | | Symposium 27: Are endogenous testosterone levels predictors of cardiovascular events?
Location: Hall B
Chairs: Chair(s): C. Wang (USA) & K. Channer (UK)
|
| 13:15 | S27.1 S27.1 | Androgen action on the cardiovascular system
K. Channer (UK) |
| | | |
| 13:45 | S27.2 S27.2 | Testosterone deficiency, cardiometabolic and mortality risks in men: the European Male Ageing Study (EMAS)
F. Wu (UK) |
| | | |
| 14:15 | S27.3 S27.3 | Endogenous androgens, diabetes, and cardiovascular disease in women: The rancho bernado study
E. Barrett-Connor (USA) |
| | | |
| 13:15 14:45 | | Symposium 28: Osteoporosis treatment in 2012 and beyond
Location: Hall C
Chairs: Chair(s): G. Borretta (Italy) & J. Stepan (Czech Republic)
|
| 13:15 | S28.1 S28.1 | Controversial issues with bisphosphonate treatment
S. Papapoulos (The Netherlands) |
| | | |
| 13:45 | S28.2 S28.2 | Sclerostin - a key bone regulatory molecule
M. Robinson (USA) |
| | | |
| 14:15 | S28.3 S28.3 | Other emerging therapies
P. Ebeling (Australia) |
| | | |
| 13:15 14:45 | | Symposium 29: Are we ready for novel therapies in obesity?
Location: Hall D
Chairs: Chair(s): F. Giorgino (Italy) & U. Pagotto (Italy)
|
| 13:15 | S29.1 S29.1 | GI Hormone-based polypharmacy for the treatment of obesity
M. Tschoep (Germany) |
| | | |
| 13:45 | S29.2 S29.2 | Growth hormone replacement and metabolic syndrome in GH deficient adults
D. Clemmons (USA) |
| | | |
| 14:15 | S29.3 S29.3 | The ghrelin-GOAT system links dietary lipids with the endocrine control of energy balance
P. Pfluger (Germany) |
| | | |
| 13:15 14:45 | | Symposium 30: New developments in pituitary adenomas
Location: Hall E
Chairs: Chair(s): G. Raverot (France) & G. Lombardi (Italy)
|
| 13:15 | S30.1 S30.1 | New developments in pituitary adenoma cytokines & other new genes in pituitary adenomas
E. Arzt (Argentina) |
| | | |
| 13:45 | S30.2 S30.2 | 'Dopastatin': an evolving story
T. Brue (France) |
| | | |
| 14:15 | S30.3 S30.3 | The use of temozolomide in pituitary tumours
A. McCormack (Australia) |
| | | |
| 13:15 14:45 | | Symposium 31: Progress in treatment in primary aldosteronism
Location: Hall F
Chairs: Chair(s): J. Widimsky (Czech Republic) & P. Mulatero (Italy)
|
| 13:15 | S31.1 S31.1 | Epidemiology and diagnosis of primary aldosteronism
P-F. Plouin (France) |
| | | |
| 13:45 | S31.2 S31.2 | Surgery
M. Walz (Germany) |
| | | |
| 14:15 | S31.3 S31.3 | Medical treatment
L. Sechi (Italy) |
| | | |
| 13:15 14:45 | | Symposium 32: Disorders of sex development (DSD)
Location: G
Chairs: Chair(s): P. Lee (USA) & P. Cohen-Kettenis (The Netherlands)
|
| 13:15 | S32.1 S32.1 | Genetics of disorders of sex development
T. Ogata (Japan) |
| | | |
| 13:45 | S32.2 S32.2 | Psychosocial and psychosexual outcome in DSD
P. Cohen-Kettenis (The Netherlands) |
| | | |
| 14:15 | S32.3 S32.3 | Review of clinical guidelines
F. Ahmed (UK) |
| | | |
| 13:15 14:45 | | Symposium 33: Environment Induced Endocrine Disease
Location: Hall H
Chairs: Chair(s): M. Shupnik (USA) & J. Toppari (Finland)
|
| 13:15 | S33.1 S33.1 | Pollution related acromegaly
S. Cannavo (Italy) |
| | | |
| 13:45 | S33.2 S33.2 | Exposure to endocrine disrupting chemicals may interfere with reproductive development in humans and affect timing of puberty
K. Main (Denmark) |
| | | |
| 14:15 | S33.3 S33.3 | Effect of iodine intake on thyroid disease in China
W. Teng (China) |
| | | |
| 14:45 15:15 | | Coffee, Posters & Exhibition
Exhibition Hall & Poster Hall
|
| 15:15 16:45 | | Symposium 34: Effects of thyroid hormone derivatives
Location: Main Hall
Chairs: Chair(s): P. Laurberg (Denmark) & F. Monaco (Italy)
|
| 15:15 | S34.1 S34.1 | Pathways of thyroid hormone metabolism
J. Koehrle (Germany) |
| | | |
| 15:45 | S34.2 S34.2 | Thyroid hormone mimetic compounds
T. Scanlan (USA) |
| | | |
| 16:15 | S34.3 S34.3 | Trials of thyroid hormone analogues
P. Ladenson (USA) |
| | | |
| 15:15 16:45 | | Symposium 35: Endocrinology and the Olympics: Will hormones help to win?
Location: Hall A
Chairs: Chair(s): E. Ghigo (Italy) & R. Ross (UK)
|
| 15:15 | S35.1 S35.1 | Does the high performance athlete need hormone replacement?
L. Di Luigi (Italy) |
| | | |
| 15:45 | S35.2 S35.2 | Can an endocrine patient participate in high performance sports?
R. Auchus (USA) |
| | | |
| 16:15 | S35.3 S35.3 | Hormone abuse in sports: the knowns and unknowns
M. Thevis (Germany) |
| | | |
| 15:15 16:45 | | Symposium 36: Bone and metabolism
Location: Hall B
Chairs: Chair(s): J.Eisman (Australia) & J.J.Body (Belgium)
|
| 15:15 | S36.1 S36.1 | Leptin and bone signalling
S. Takeda (Japan) |
| | | |
| 15:45 | S36.2 S36.2 | Insulin bone axis
T. Clemens (USA) |
| | | |
| 16:15 | S36.3 S36.3 | Functions and mode of action of osteocalcin
G. Karsenty (USA) |
| | | |
| 15:15 16:45 | | Symposium 37: Diabetes and cancer
Location: Hall C
Chairs: Chair(s): L. Bach (Austria) & A. Abdel Raheem (Egypt)
|
| 15:15 | S37.1 S37.1 | Epidemiological evidence for a link between diabetes and cancer
A. Renehan (UK) |
| | | |
| 16:00 | S37.2 S37.2 | The role of the insulin receptor in cancer
A. Belfiore (Italy) |
| | | |
| 15:15 16:45 | | Symposium 38: Craniopharyngioma: Hypothalamic complications
Location: Hall D
Chairs: Chair(s): J. Hamilton (Canada) & M. Puig-Domingo (Spain)
|
| 15:15 | S38.1 S38.1 | Childhood craniopharyngioma
H. Müller (Germany) |
| | | |
| 15:45 | S38.2 S38.2 | Hypothalamic disorders in craniopharyngioma; relevance to clinical practice
C. Thompson (Ireland) |
| | | |
| 16:15 | S38.3 S38.3 | Management of hypothalamic obesity in patients with craniopharyngioma
G. Wittert (Australia) |
| | | |
| 15:15 16:45 | | Symposium 39: Adrenal insufficiency
Location: Hall E
Chairs: Chair(s): W. Arlt (UK) & C. Betterle (Italy)
|
| 15:15 | S39.1 S39.1 | Pathomechanism underlying adrenoleucodystrophy
G. Raymond (USA) |
| | | |
| 15:45 | S39.2 S39.2 | Molecular pathomechanisms of steroidogenetic adrenal disorders
F. Riepe (Germany) |
| | | |
| 16:15 | S39.3 S39.3 | New developments in the immunology of Addison's disease
E. Husebye (Norway) |
| | | |
| 15:15 16:45 | | Symposium 40: New familial endocrine cancer syndromes: pathophysiology and counselling
Location: Hall F
Chairs: Chair(s): E. Lalli (France) & D. Malkin (Canada)
|
| 15:15 | S40.1 S40.1 | DICER1 mutations characterize a novel syndrome with endocrine features
W. Foulkes (Canada) |
| | | |
| 15:45 | S40.2 S40.2 | The paediatric patient with paraganglioma syndrome
M. Robledo (Spain) |
| | | |
| 16:15 | S40.3 S40.3 | Li-Fraumeni syndrome: A paradigm of genetic testing to clinical surveillance for pediatric endocrine tumors
D. Malkin (Canada) |
| | | |
| 15:15 16:45 | | Symposium 41: The endocrinology of adipose tissue
Location: Hall G
Chair: Chair(s): M. Luconi (Italy)
|
| 15:15 | S41.1 S41.1 | Physiological and neuronal determinants of brown adipose tissue-mediated thermogenesis in small mammals and humans
D. Richard (Canada) |
| | | |
| 15:45 | S41.2 S41.2 | Obesity and insulin resistance: the cross-talk macrophage-adipocyte view
J. Fernandez-Real (Spain) |
| | | |
| 16:15 | S41.3 S41.3 | The fat cell: dynamics, genomics and adipokines
P. Arner (Sweden) |
| | | |
| 15:15 16:45 | | Symposium 42: Novel insights into regulation of puberty
Location: Hall H
Chairs: Chair(s): E. Malecka-Tendera (Poland) & M. Cappa (Italy)
|
| 15:15 | S42.1 S42.1 | Central networks controlling the timing of puberty
A. Lomniczi (USA) |
| | | |
| 15:45 | S42.2 S42.2 | Re-wiring the hypothalamus with new peptides to control puberty
V. Navarro (USA) |
| | | |
| 16:15 | S42.3 S42.3 | Novel insights into regulation of puberty: lessons from human genetics
B. Mendonca (Brazil) |
| | | |
| 16:35 17:10 | | JOE / JME Prize Presentation
Location: Main Hall
Chair: Chair(s): A. Clark (UK)
|
| 17:10 17:55 | | Fondation IPSEN 2012 Endocrine Regulation Prize
Location: Main Hall
|
| 17:10 | IFPL1 IFPL1 | Wylie Vale Endocrine Prize Lecture at the 2012 ICE/ECE Congress
P. Sassone Corsi (USA) |
| | | |
| 17:55 19:30 | | Poster Reception
Attended poster session, refreshments available
Poster Hall
|
| 18:30 20:00 | | IPSEN Satellite Symposia - Acromegaly: patient-focused disease control and long-term outcomes
Location: Hall B
|
| 18:30 | | Welcome
E. Ghigo (Italy) |
| | | |
| 18:35 | | Biochemical determinants of long-term outcomes
S. Lamberts (The Netherlands) |
| | | |
| 18:55 | | Clinical determinants of long-term outcomes
A. Giustina (Italy) |
| | | |
| 19:15 | | Therapeutic determinants of long-term outcomes
M. Gadelha (Brazil) |
| | | |
| 19:35 | | Economic burden of long-term acromegaly management
S. Melmed (USA) |
| | | |
| 19:55 | | Summary and close
S. Melmed (USA) |
| | | |
| 18:30 20:00 | | NOVARTIS Satellite Symposia - Taking the next step: improving outcomes in patients with pituitary tumors
Location: Main Hall
Chair: A-M. Colao (Italy)
|
| 18:30 | | Welcome and Introduction
A-M. Colao (Italy) |
| | | |
| 18:35 | | Advancing the partnership: A multidisciplinary approach to treating Cushing's disease
P. Cappabianca (Italy) |
| | | |
| 18:50 | | Walking in their shoes: Case studies of Cushing's disease
I. Shimon (Israel) |
| | | |
| 19:05 | | Toeing the line: Criteria for and achievement of control in acromegaly
J. Wass (UK) |
| | | |
| 19:20 | | Striding towards the future: Somatostatin analogues for acromegaly
A-M. Colao (Italy) |
| | | |
| 19:40 | | Panel discussion
A-M. Colao (Italy), P. Cappabiance (Italy), I. Shimon (Israel), J. Wass (UK)
|
| | | |
| 19:55 | | Concluding remarks
A-M. Colao (Italy) |
| | | |
| 18:30 20:00 | | PROSTRAKAN Satellite Symposia - Testosterone replacement therapy - benefits & risks?
Location: Hall F
Chair: M. Maggi
|
| 18:30 | | Welcome, Opening Remarks & Introduction
M. Maggi (Florence, Italy) |
| | | |
| 18:35 | | Testosterone - emerging data for the management of hypogonadel men with Type 2 diabetes
H. Jones (Barnsley, UK) |
| | | |
| 19:00 | | Testosterone - emerging data for the management of hypogonadel men with heart disease
K. Channer (Sheffield, UK) |
| | | |
| 19:25 | | Testosterone replacement therapy and prostate diseases
M. Maggi (Florence, Italy) |
| | | |
| 19:50 | | Q&A and Chairman's Concluding Comments
|
| | | |
| 20:30 21:15 | | ICE/ECE 2012 Congress Concert
Tickets should be purchased during registration
Basilica di San Lorenzo
|